Valuation
26% of the score, 30% here after data gaps
0median 56
An operating loss over the last year: there are no earnings to price.
RYTMRhythm Pharmaceuticals, Inc.
$98.48-1.3% 1Y
$98.48
$75.8252 weeks$117.62
RyuScore
Seven criteria, each scored 0 to 100 on a published scale, weighted into one number.
RyuScore 18 out of 100, Weak
Weak. Rhythm Pharmaceuticals, Inc. scores higher than 15% of the 1,794 companies Ryufin scores.
Carried by earnings quality, held back by valuation and return on capital.
Healthcare median 28 · all companies 57
How the score has moved
At each fiscal year end, from the reports and price of the time6
0
5
18
18
18
18
202020212022202320242025today
The biggest move was up 13 points from 2022 to 2023, mostly capital allocation.
Return on capital
18% of the score, 20% here after data gaps
0median 34
Over 7 years the business earned -2974% a year after tax on the capital it uses.
2%
8%
15%
25%
-2974%
None at 2% or less, full points from 25%full points
7 years agolatest n/a
Return on new capital
16% of the score, 18% here after data gaps
0median 49
No operating profit over the period, so nothing was earned to reinvest.
Capital allocation
14% of the score, 16% here after data gaps
40median 64
How management spends the money: shares bought back or issued, and whether assets grow faster than the business they serve.
Share countUp 8.1% a year over 5 years: new shares
05%
-3%
8.1%
0 pointsfull points
Assets against salesAssets grew 9.9% a year, sales 179%
10012%
-2%
-169%
0 pointsfull points
Cycle position
Taken out: its 12% is shared by the others
n/ano data
Margins have been too thin to measure a cycle against.
Balance sheet
8% of the score, 9% here after data gaps
50median 50
What the debt weighs against the profit that has to carry it.
Net debt to EBITDAMore cash than debt
100Interest coverOperating profit covers interest -11x
01.5x
12x
-10.9x
0 pointsfull points
Earnings quality
6% of the score, 7% here after data gaps
100median 90
Whether the reported profit arrives as cash, and whether the accounts show the usual signs of stretching.
AccrualsCash ran ahead of profit by 18.5% of assets
1008%
0%
-8%
-19%
0 pointsfull points
Beneish M-scoreTaken out: sales grew 46% in a year, and the model flags that much growth on its own
n/aHow the RyuScore works
Each criterion earns 0 to 100 points on the scale drawn under it, and the RyuScore is their average weighted 26, 18, 16, 14, 12, 8 and 6. Scales bend in the company's favour between their ends, so an ordinary figure is never already near zero. For RYTM, cycle position could not be measured from the filings, so it is taken out and the remaining weights scale up.
Built from the company's annual and quarterly filings with the SEC and today's share price. Banks, insurers and property trusts are not scored: their debt is their raw material, so these yardsticks mean something else there. Figures as of 2026-06-30, latest annual report FY2025.